Latest Intelligence on Pharmaceutical Contract Research Organizations

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vertex: Positive results for cystic fibrosis drug

Vertex has completed a Phase II trial of a small-molecule oral drug, VX-770, which targets the basic defect that occurs in cystic fibrosis (CF). The trial has only been performed in 20 patients from a small, genetically distinct subset of the CF population. However, the results are encouraging and indicate an alternative approach to traditional reactive management of CF.

Published By Datamonitor
28 Mar 2008
Expert View
Expert View

The paperless clinical trial: closer than you think

Life sciences companies globally are turning to eClinical solutions in a bid to cut costs during clinical trials. On average, life science companies spend between $12-17m yearly on mailings and copies of paper case report forms. With the implementation of eClinical solutions, a company could save anywhere from $10-15m a year on paper and postage alone, according to a new report by Datamonitor.

Published By Datamonitor
07 Aug 2008
CommentWire
CommentWire

Takeda/J&J: EU recommendation positions Velcade for first-line myeloma approval

Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients. Velcade would see considerable uptake if the drug is approved in the first-line setting, due to its proven activity and favorable safety profile compared to current treatment regimens.

Published By Datamonitor
28 Jul 2008
CommentWire
CommentWire

Roche: new MabThera data challenges anti-TNFs

New data from Roche's IMAGE study presented at the European League Against Rheumatism congress show that administering MabThera at first-line may significantly slow joint damage and improve clinical outcomes in patients with rheumatoid arthritis. However, Datamonitor does not predict that these data will change the current treatment paradigms, as touted by the investigators.

Published By Datamonitor
12 Jun 2009
Expert View
Expert View

Pharmacovigilance solutions: essential for the future of healthcare

Although many newer pharmacovigilance solutions are still in the nascent stages, and despite pharmaceutical companies' reluctance to adopt them, it is becoming increasingly obvious that these tools will play an essential role in protecting public health. As drug safety regulations increase, signal detection technologies will aid in the costly act of identifying and managing adverse drug events.

Published By Datamonitor
06 Jun 2008
CommentWire
CommentWire

Pfizer: development setbacks cast doubt over Sutent

For the third time in 2009, Pfizer has terminated a Phase III study of Sutent, this time in metastatic colorectal cancer. Although the drug remains likely to achieve blockbuster sales within its existing approved indications, this latest setback casts further doubt over its clinical potential in larger, more lucrative indications.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

Pfizer: breakthrough for neuroendocrine tumor therapy

Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.

Published By Datamonitor
13 Mar 2009
CommentWire
CommentWire

Orexigen: Contrave joins the list of failed weight-loss drugs

The FDA has issued a Complete Response Letter informing Orexigen that its developmental obesity therapy Contrave will require additional clinical study if it is to reach the market. The financial burden of an outcomes study and uncertainties regarding the drug's effect on blood pressure is likely to prevent Contrave from entering the market.

Published By Datamonitor
02 Feb 2011
Expert View
Expert View

Online recruitment is streamlining clinical trials

The clinical drug trials required to ensure that the next blockbuster makes it to market often last longer than expected. The majority of these delays can be attributed to patient recruitment problems, arising from arduous processes and negative public perceptions. According to a new report by Datamonitor, however, the internet is proving to be an invaluable tool in streamlining recruitment.

Published By Datamonitor
22 Jul 2008
CommentWire
CommentWire

Noven: Mesafem emerges as potential alternative to HRT

Recently announced results suggest that Noven's non-hormonal therapy Mesafem is effective in relieving vasomotor symptoms associated with the menopause. However, Datamonitor believes that Mesafem will have to demonstrate equivalent or superior efficacy to hormonal replacement therapy if it is to overcome the challenges in this underserved market.

Published By Datamonitor
17 Jul 2009

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.